Syndax Pharmaceuticals, Inc (Nasdaq: SNDX), a clinical stage biopharmaceutical company, announced on Wednesday that it has named Martin H Huber, MD as a new director.
Dr Huber has more than 20 years of academic, biotechnology, and pharmaceutical drug development experience. He is currently the President of R&D and Chief Medical Officer of Xilio Therapeutics, Inc. He has held the position of senior vice president, chief medical officer at TESARO, Inc, becoming senior vice president, Clinical following its acquisition by GlaxoSmithKline plc. He has also held the position of vice president, Oncology Clinical Research at Merck Research Laboratories.
Huber has an MD from Baylor College of Medicine.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer